#obesity treatment
6 stories
Eli Lilly Price Target Boost
Berenberg upgrades Eli Lilly to Buy with 20% upside potential.
Yahoo Finance · 1m
Viking Soars Alone as Obesity Complex Shrugs
Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move.
24/7 Wall St. · 1m
Lilly captures 70% of new Medicare GLP-1 patients
Eli Lilly CEO says 700,000 seniors started weight loss drugs after Medicare coverage launched in July, with Lilly drugs taking the majority.
CNBC · 1m
Obesity drug cuts weight by 25 percent in trial
Retatrutide, a triple-acting hormone treatment from Eli Lilly, showed the strongest weight loss results yet in late-stage testing.
Ars Technica · 2m
Lilly claims one-third of new GLP-1 pill patients
Eli Lilly CEO says Foundayo is capturing a third of new oral GLP-1 patients as the company breaks ground on a six point five billion dollar Houston manufacturing facility.
CNBC · 1m
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
24/7 Wall St. · 1m